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1. Introduction 
Polyurethanes (PU) are an important class of polymers that have found many applications 
as biomaterials due to their excellent physical properties and relatively good 
biocompatibility. Basically, PU may be produced by two chemical processes: by 
polycondensation of a diamine with bischloroformates or by reaction between a diol and a 
diisocyanate. Many biomedical devices are made from segmented PU such as catheters, 
blood pumps, prosthetic heart valves and insulation for pacemakers (Lelah & Cooper, 1986, 
Lamba et al., 1997). A promising approach for the development of new controlled-releasing 
preparations is use of PU as the carriers in drug delivery systems.  
Drug delivery systems have been progressively developed in the field of therapeutic 
administration owing to their advantages: providing drug concentration over a period of 
prolonged action, decreasing the total therapeutic dose and reducing the undesirable side 
effects, and, hence, improving the pharmaceutical efficiencies. These are achieved by the use 
of the controlled-release drug delivery systems (Hsien, 1988). Controlled release dosage 
forms are consist of the pharmacological agent and the polymer carrier that regulate its 
release. In general two types of drug delivery systems have been used: diffusion-controlled 
systems and dissolution-controlled systems. In the first cause the drug is usually dispersed 
or dissolved in the solid reservoir or membrane and the kinetics of drug release are 
generally controlled by diffusion through the polymer. In the second cause the drug are 
generally incorporated into a water-soluble or water-swellable polymer and the release of 
drug is controlled by swelling and dissolution of polymer. In both the causes polymer 
function is a principal component which controls the transport and the release rate of drug 
molecule. To be a useful drug carrier, a polymer needs to possess certain features. The 
polymeric carrier has to be non-toxic, non-immunogenic and biocompatible; the carrier must 
contain an effective dose of active agent; the material of system must be biodegradable and 
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form biologically acceptable degradation products; the rate of drug release from the carrier 
must occur at an acceptable rate; the carrier must be able to be easily sterilized. 
The design of the PU controlled-release forms for therapeutic drug administration is the 
subject of intense interest. Such systems are being used for sustained and controlled delivery 
of various pharmaceutical agents such as prednisolon (Sharma et al., 1988), morphine, 
caffeine (Graham et al., 1988), prostaglandin (Embrey et al., 1986) and theophylline (Reddy 
et al., 2006). The PU carrier is utilized to deliver iodine-containing drugs (Touitou & 
Friedman, 1984). Urethane-based hydrogels were prepared based on the reaction of 
diisocyanates with amphilic ethylene oxide and triol crosslinker to deliver propranolol 
hydrochloride, an antihypertensive drug (Van Bos & Schacht, 1987). Drug delivery systems 
on a PU base with various antitumorous drugs, such as cyclophosphane, thiophosphamide 
and vincristine, have been prepared (Iskakov et al., 1998, 2000). An in vitro technique was 
used to determine the release characteristics of the drugs into model biological media. It was 
shown the drug release occurs in accordance with first-order kinetics. 
PU-based drug delivery systems have considerable potential for treatment of tuberculosis. 
Tuberculosis is widely spread disease in most developing countries. The main method of 
tuberculosis treatment is chemotherapy. Although current chemotherapeutic agents for 
tuberculosis treatment are therapeutically effective and well tolerated, a number of 
problems remain. The chemotherapy is burden some, extends over long periods and 
requires continuous and repeated administration of large drug doses. Thus, traditional drug 
chemotherapy has serious limitations because of increasing microbial drug resistance and 
toxico-allergic side effects. One of the ultimate problems in effective treatment of 
tuberculosis is patient compliance. These problems of increasing drug resistance, toxico-
allergic side effects, patient compliance can be approached by the use of long-acting 
polymeric drug delivery systems (Sosnik et al., 2010). The design of implantable systems 
containing the antituberculosis drugs in combination with biocompatible polymers would 
make possible to achieve the significant progress in treatment of this global debilitating 
disease (Shegokar et al., 2011). 
Biodegradable microsphere drug delivery systems have shown application for oral and 
parenteral administration. Administration of microparticles to the lungs (alveolar region) 
may provide the opportunity for the prolonged delivery active agent to tuberculosis 
infected macrophages. Microspheres can be produced to meet certain morphological 
requirements such as size, shape and porosity by varying the process parameters. However, 
the morphology of the lung is such that to achieve effective drug deposition it is necessary 
to control the particle size of microparticles. 
The objective of the chapter is to develop an effective polymeric drug delivery systems 
based on PU for the treatment of tuberculosis. Polyurethane materials are investigated as 
carriers for sustained and controlled release of antituberculosis drugs. The synthesis and 
characterization of PU microcapsules are studied making use various molecular weight 
polyethylene glycol and tolylene-2,4-diisocyanate. Antituberculosis drug isoniazid (Is), 
rifampicin, ethionamide and florimicin were incorporated into the PU microcapsules and 
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foams. The effects of nature and concentration of drugs and diols, molecular weight (Mw), 
morphology of polyurethanes on release behavior from polymeric systems were studied. 
The possibility of application of the polymeric drug delivery systems based on polyurethane 
for tuberculosis treatment was shown by some medical and biological tests. 
2. Polymeric microparticles for tuberculosis treatment 
Recent trends in polymeric controlled drug delivery have seen microencapsulation of 
pharmaceutical substances in biodegradable polymers as an emerging technology. Extensive 
progressive efforts have been made to develop various polymeric drug delivery systems to 
either target the site of tuberculosis infection or reduce the dosing frequency (Toit et al., 
2006). Carriers as microspheres have been developed for the sustained delivery of 
antituberculosis drugs and have demonstrated better chemotherapeutic efficacy when 
investigated in animal models. Antituberculosis drugs have been successfully entrapped in 
microparticles of natural and synthetic polymers such as alginate (ALG), ALG-chitosan, 
poly-lactide-co-glycolide and  poly-butyl cyanoacrylate (Gelperina et al., 2005, Pandey & 
Khuller, 2006). 
ALG, a natural polymer, has attracted researchers owing to its ease of availability, 
compatibility with hydrophobic as well as hydrophilic molecules, biodegradability under 
physiological conditions, lack of toxicity and the ability to confer sustained release potential. 
The ability of ALG to co-encapsulate multiple antitubercular drugs and offer a controlled 
release profile is likely to have a major impact in enhancing patient compliance for better 
management of tuberculosis (Ahmad & Khuller, 2008). 
Spherical microspheres able to prolong the release of Is were produced by a modified 
emulsification method, using sodium ALG as the hydrophilic carrier (Rastogi et al., 2007). 
The particles were heterogeneous with the maximum particles of an average size of 3.719 
μm. Results indicated that the mean particle size of the microspheres increased with an 
increase in the concentration of polymer and the cross-linker as well as the cross-linking 
time. The entrapment efficiency was found to be in the range of 40-91%. Concentration of 
the cross-linker up to 7.5% caused increase in the entrapment efficiency and the extent of 
drug release. Optimized Is-ALG microspheres were found to possess good bioadhesion. The 
bioadhesive property of the particles resulted in prolonged retention in the small intestine. 
Microspheres could be observed in the intestinal lumen at 4h and were detectable in the 
intestine 24h post-oral administration. Increased drug loading (91%) was observed for the 
optimized formulation suggesting the efficiency of the method. Nearly 26% of Is  was 
released in simulated gastric fluid pH 1.2 in 6h and 71.25% in simulated intestinal fluid  pH 
7.4 in 30h.  
ALG microparticles were developed as oral sustained delivery carriers for antituberculosis 
drugs in order to improve patient compliance (Qurrat-ul-Ain et al., 2003). Pharmacokinetics 
and therapeutic effects of ALG microparticle encapsulated Is, rifampicin and pyrazinamide 
were examined in guinea pigs. ALG microparticles containing antituberculosis drugs were 
evaluated for in vitro and in vivo release profiles. These microparticles exhibited sustained 
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release of Is, rifampicin and pyrazinamide for 3-5 days in plasma and up to 9 days in organs. 
Peak plasma concentration, elimination half-life and infinity of ALG drugs were 
significantly higher than those of free drugs. The encapsulation of drug in ALG 
microparticles resulted in up to a nine-fold increase in relative bioavailability compared 
with free drugs. Chemotherapeutic efficacy of ALG drug microspheres against experimental 
tuberculosis not detectable at 1:100 and 1:1000 dilutions of spleen and lung homogenates. 
Histopathological studies further substantiated these observations, thus suggesting that 
application of ALG-encapsulated drugs could be useful in the effective treatment of 
tuberculosis. 
Pharmacokinetics and tissue distribution of free and ALG-encapsulated antituberculosis 
drugs were evaluated in mice at different doses (Ahmad et al., 2006). ALG nanoparticles 
encapsulating Is, rifampicin, pyrazinamide and ethambutol were prepared by controlled 
cation-induced gelification of ALG. The formulation was orally administered to mice at two 
dose levels. A comparison was made in mice receiving free drugs at equivalent doses. The 
relative bioavailabilities of all drugs encapsulated in ALG nanoparticles were significantly 
higher compared with free drugs. Drug levels were maintained at or above the minimum 
inhibitory concentration until 15 days in organs after administration of encapsulated drugs, 
whilst free drugs stayed at or above 1 day only irrespective of dose. The levels of drugs in 
various organs remained above the minimum inhibitory concentration  at both doses for 
equal periods, demonstrating their equiefficiency.  
Chemotherapeutic potential of ALG nanoparticle-encapsulated econazole and 
antituberculosis drugs were studied against murine tuberculosis (Ahmad et al., 2007). 
Econazole (free or encapsulated) could replace rifampicin and Is during chemotherapy. 
Eight doses of ALG nanoparticle-encapsulated econazole or 112 doses of free econazole 
reduced bacterial burden by more than 90% in the lungs and spleen of mice infected with 
Mycobacterium tuberculosis. ALG nanoparticles reduced the dosing frequency of azoles 
and antitubercular drugs by 15-fold.  
Is was encapsulated into microspheres of ALG-chitosan by means of a complex coacervation 
method in an emulsion system (Lucinda-Silva & Evangelista, 2003). The particles were 
prepared in three steps:  preparation of a  emulsion phase and adsorption of the drug. The 
results showed that microspheres of ALG-chitosan obtained were of spherical shape. The 
emulsion used for microparticle formation allows the preparation of particles with a narrow 
size distribution. The adsorption observed is probably of chemical nature, i.e. there is an 
ionic interaction between the drug and the surface of the particles. 
ALG-chitosan microspheres encapsulating rifampicin, Is and pyrazinamide, were 
formulated (Pandey & Khuller, 2004). A therapeutic dose and a half-therapeutic dose of the 
microsphere-encapsulated were orally administered to guinea pigs for pharmacokinetic and 
chemotherapeutic evaluations. The drug encapsulation efficiency ranged from 65% to 85% 
with a loading of 220-280 mg of drug per gram microspheres. Administration of a single oral 
dose of the microspheres to guinea pigs resulted in sustained drug levels in the plasma for 7 
days and in the organs for 9 days. In Mycobacterium tuberculosis H37Rv-infected guinea 
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pigs, administration of a therapeutic dose of microspheres spaced 10 days apart produced a 
clearance of bacilli equivalent to conventional treatment for 6 weeks.  
Polylactide-co-glycolide (PLG) polymers are biodegradable and biocompatible, they have 
been the most commonly used as carriers for microparticle formulations. Monodispersed 
poly-lactic-co-glycolic acid (PLGA) microspheres containing rifampicin have been prepared 
by solvent evaporation method (Makino et al., 2004, Yoshida et al., 2006). The microspheres 
were spherical and their average diameter was about 2 μm. The loading efficiency of 
rifampicin was dependent on the molecular weight of PLGA. The higher loading efficiency 
was obtained by the usage of PLGA with the lower Mw, which may be caused by the 
interaction of the amino groups of rifampicin with the terminal carboxyl groups of PLGA. 
PLGA with the monomer compositions of 50/50 and 75/25, of lactic acid/glycolic acid, were 
used in this study. From rifampicin-loaded PLGA microspheres formulated using PLGA 
with the Mw of 20,000, rifampicin was released with almost constant rate for 20 days after 
the lag phase was observed for the initial 7 days at pH 7.4. On the other hand, from 
rifampicin-loaded PLGA microspheres formulated using PLGA with the molecular weight 
of 5000 or 10,000, almost 90% of rifampicin-loaded in the microspheres was released in the 
initial 10 days. Highly effective delivery of rifampicin to alveolar macrophages was 
observed by the usage of rifampicin-loaded PLGA microspheres. Almost 19 times higher 
concentration of rifampicin was found to be incorporated in alveolar macrophages when 
rifampicin-loaded PLGA microspheres were added to the cell culture medium than when 
rifampicin solution was added. 
Controlled release rifampicin-loaded microspheres were evaluated in nonhuman primates 
(Quenelle et al., 2004). These microsheres were prepared by using biocompatible polymeric 
excipients of lactide and glycolide copolymers. Animals received either 2.0 g of a large 
formulation (10–150 mcm, 23 wt% rifampicin) injected subcutaneously at Day 0 (118–139 mg 
rifampin/kg), 4.0 g of a small formulation (1–10 mcm, 5.8 wt% rifampicin) administered 
intravenously in 2.0 g doses on Day 0 and 7 (62.7–72.5 mg rifampicin/kg), or a combination 
of small and large microspheres (169–210 mg rifampin/kg). Extended rifampicin release was 
observed up to 48 days. Average rifampicin concentrations remaining in the liver, lung, and 
spleen at 30 days were 14.03, 4.09, and 1.98 μg/g tissue, respectively. 
PLG nanoparticles encapsulating streptomycin were prepared by the multiple emulsion 
technique and administered orally to mice for biodistribution and chemotherapeutic studies 
(Pandey & Khuller, 2007). The mean particle size was 153.12 nm with 32.12±4.08% drug 
encapsulation and 14.28±2.83% drug loading. Streptomycin levels were maintained for 4 
days in the plasma and for 7 days in the organs following a single oral administration of 
PLG nanoparticles. There was a 21-fold increase in the relative bioavailability of PLG-
encapsulated streptomycin compared with intramuscular free drug. In Mycobacterium 
tuberculosis (M.tuberculosis) H37Rv infected mice, eight doses of the oral streptomycin 
formulation administered weekly were comparable to 24 intramuscular injections of free 
streptomycin.  
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PLG nanoparticle-encapsulated econazole and moxifloxacin  have been evaluated against 
murine tuberculosis  (drug susceptible) in order to develop a more potent regimen for 
tuberculosis  (Ahmad et al., 2008). PLG nanoparticles were prepared by the multiple 
emulsion and solvent evaporation technique and were administered orally to mice. A single 
oral dose of PLG nanoparticles resulted in therapeutic drug concentrations in plasma for up 
to 5 days (econazole) or 4 days (moxifloxacin), whilst in the organs (lungs, liver and spleen) 
it was up to 6 days. In comparison, free drugs were cleared from the same organs within 12-
24h. In M. tuberculosis-infected mice, eight oral doses of the formulation administered 
weekly were found to be equipotent to 56 doses (moxifloxacin administered daily) or 112 
doses (econazole  administered twice daily) of free drugs. Furthermore, the combination of 
moxifloxacin+econazole  proved to be significantly efficacious compared with individual 
drugs. Addition of rifampicin to this combination resulted in total bacterial clearance from 
the organs of mice in 8 weeks. PLG nanoparticles appear to have the potential for 
intermittent therapy of tuberculosis, and combination of moxifloxacin, econazole  and 
rifampicin  is the most potent. 
Antituberculosis drugs Is, rifampicin, streptomycin and moxifloxacin have been 
encapsulated in poly(butyl cyanoacrylate) nanoparticles (Anisimova et al., 2000, Kisich et al, 
2007). Incorporation of drugs in polymeric nanoparticles not only increased the intracellular 
accumulation  of these drugs in the cultivated human blood monocytes but also produced 
enhanced antimicrobial activity of these agents against intracellular M. tuberculosis 
compared with their activity in extracellular fluid. Encapsulated moxifloxacin accumulated 
in macrophages approximately three-fold times more efficiently than the free drug, and was 
detected in the cells for at least six times longer than free moxifloxacin at the same 
extracellular concentration. 
This brief review suggested that micro- and nanoparticles based delivery systems have a 
considerable potential for treatment of tuberculosis. Their major advantages, such as 
improvement of drug bioavailability and reduction of the dosing frequency, may create a 
sound basis for better management of the disease, making directly observed treatment more 
practical and affordable.  
3. Polyurethane microparticles as carriers of drug  
PU microspheres can be prepared by interfacial polycondensation in emulsions. These 
techniques include polycondensation of two or more complimentary monomers at the 
interface of two-phase system, carefully emulsified for obtaining little drop-lets in emulsion 
phase. Usually, the interfacial polycondensation carried out by two steps: emulsification 
step (emulsion formation using a mechanical stirring during few minutes and one of the 
monomers is dissolved in the emulsion drops; polycondensation step (the second 
complementary monomer is added to the external phase of the emulsion and the 
polycondensation reaction takes place at the liquid-liquid emulsion interface). Interest in the 
PU microparticles in each day has being increased since products presents numerous 
advantages in  biomedical, pharmaceutical and cosmetic applications.  
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PU microparticles could be interesting matrices for controlled drug delivery. Aliphatic PU 
Tecoflex was evaluated as  microsphere matrix for the controlled release of theophylline 
(Subhaga et al., 1995). PU microspheres were prepared using solvent evaporation technique 
from a dichloromethane solution of the polymer containing the drug. A dilute solution of 
poly(vinyl alcohol) served as the dispersion medium. Microspheres of good spherical 
geometry having theophylline content of 35% could be prepared by the technique. The 
release of the drug from the microspheres was examined in simulated gastric and intestinal 
fluids. While a large burst effect was observed in gastric fluid, in the intestinal fluid a close 
to zero-order release was seen.  
Microencapsulation of theophylline in PU was developed with 4, 4'-methylene-
diphenylisocyanate, castor oil and ethylene diamine as chain extender (Rafienia et al., 2006). 
PU microspheres were prepared in two steps pre-polymer preparation and microspheres 
formation. Particle size investigation with optical microscopy revealed size distribution of 
27–128 μm. Controlled release experiment of theophylline was performed in phosphate 
buffered saline at pH 7.4 with UV-spectrometer at 274 nm. Drug release profiles showed 
initial release of 2–40% and further release for more than 10 days. 
The effect of chain-extending agent on the porosity and release behavior of biologically 
active agent diazinon from PU microspheres were studied (Jabbari & Khakpour, 2000). 
Microsphere was prepared using a two-step suspension polycondensation method with 
methylene diphenyl diisocyanate, polyethylene glycol 400 and 1,4-butanediol as the chain-
extending agent. Chain-extending agent was used to increase the ratio of hard to soft 
segments of the PU network, and its effect on microsphere morphology was studied with 
SEM. According to the results, porosity was significantly affected by the amount of chain-
extending agent. The pore size decreased as the concentration of chain-extending agent 
increased from zero to 50 mole%. With further increase of chain-extending agent to 60 and 
67%, PU chains became stiffer and formation of pores was inhibited. Therefore, pore 
morphology was significantly affected by variations in the amount of chain-extending agent. 
The release behavior of microspheres was investigated with diazinon as the active agent. 
After an initial burst, corresponding to 3% of the incorporated amount of active agent, the 
release rate was zero order. 
PU polymers and poly(ether urethane) copolymers were chosen as drug carriers for alpha-
tocopherol (Bouchemal et al., 2004). This active ingredient is widely used as a strong 
antioxidant in many medical and cosmetic applications, but is rapidly degraded, because of 
its light, heat and oxygen sensitivity. PU and poly(ether urethane)-based nanocapsules were 
synthesized by interfacial reaction between two monomers. Interfacial polycondensation 
combined with spontaneous emulsification is a new technique for nanoparticles formation. 
Nanocapsules were characterized by studying particle size (150-500 nm), pH, yield of 
encapsulation and morphologies. Polyurethanes were obtained from the condensation of 
isophorone diisocyanate and 1,2-ethanediol, 1,4-butanediol , 1,6-hexanediol. Poly(ether 
urethane) copolymers were obtained by replacing diols by polyethylene glycol oligomers 
Mw 200, 300, 400 and 600. Mw of di- and polyols have a considerable influence on 
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nanocapsules characteristics cited above. The increase of Mw of polyols tends to increase the 
mean size of nanocapsules from 232±3 nm using ethanediol to 615± 39 nm using PEG 600, 
and led to the agglomeration of particles. We also noted that the yield of encapsulation 
increases with the increase of polyol length. After 6 months of storage, polyurethanes 
nanocapsules possess good stability against aggregation at 4 and 25o C. Comparing results 
obtained using different monomers, it reveals that the PU based on hexanediol offers good 
protection of alpha-tocopherol against damaging caused by the temperature and UV 
irradiation (Bouchemal et al., 2006). 
Ovalbumin (OVA)-containing PU microcapsules were successfully prepared by a reaction 
between toluene diisocyanate and different polyols such as glycerol, ethane diol, and 
propylene glycol (Hong & Park, 2000). The structural and thermal properties of the resultant 
microcapsules and the release profile of the OVA from the wall membranes were studied. In 
conclusion, the microcapsules from the glycerol showed the highest thermal stability, with 
the formation of many hydrogen bonds. From the data of release profiles, it was confirmed 
that the particle size distribution and morphologies of microcapsules determined the release 
profiles of the OVA from the wall membranes. 
Bi-soft segmented poly(ester urethane urea) microparticles were prepared and characterized 
aiming biomedical application (Campos et al., 2011). Two different formulations were 
developed, using poly(propylene glycol), tolylene 2,4-diisocyanate terminated pre-polymer 
and poly(propylene oxide)-based tri-isocyanated terminated pre-polymer (TI). A second soft 
segment was included due to poly(ε-caprolactone) diol. Infrared spectroscopy, used to 
study the polymeric structure, namely its H-bonding properties, revealed a slightly higher 
degree of phase separation in TDI-microparticles. TI-microparticles presented slower rate of 
hydrolytic degradation, and, accordingly, fairly low toxic effect against macrophages. These 
new formulations are good candidates as non-biodegradable biomedical systems. 
The synthesis of PU microsphere-gold nanoparticle "core-shell" structures and their use in 
the immobilization of the enzyme endoglucanase are described (Phadtare et al., 2004). 
Assembly of gold nanoparticles on the surface of polymer microspheres occurs through 
interaction of the nitrogens in the polymer with the nanoparticles, thereby precluding the 
need for modifying the polymer microspheres to enable such nanoparticle binding. 
Endoglucanase could thereafter be bound to the gold nanoparticles decorating the PU 
microspheres, leading to a highly stable biocatalyst with excellent reuse characteristics. The 
immobilized enzyme retains its biocatalytic activity and exhibits improved thermal stability 
relative to free enzyme in solution.  
Microencapsulation of the water soluble pesticide monocrotophos (MCR), using PU as the 
carrier polymer, has been developed using two types of steric stabilizers polymethyllauril 
acrylate (PLMA) macrodiol and PLMA-g-PEO graft copolymer (Shukla et al., 2002). The 
microencapsulation process is carried out in non-aqueous medium and at a moderate 
temperature to avoid any chemical degradation of monocrotophos during the encapsulation 
process. Microcapsules were characterized by optical microscopy and SEM for particle size 
and morphology, respectively. The effects of loading of MCR, crosslinking density of PU, 
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and nature of steric stabilizer on the release of MCR from PU microcapsules have been 
studied. 
Poly(urea-urethane) microcapsules containing oil-soluble dye dioctyl phthalate as core 
material were prepared by the interfacial polymerization with using mixtures of tri- and di-
isocyanate monomers as wall forming materials (Chang et al., 2003, 2005). The time course 
of the dye release in dispersing tetrahydrofuran was measured as a function of the weight 
fraction of tri-isocyanate monomer in the total monomer weight  and the core/wall material-
weight ratio. The dye release curves were well represented by an exponential function 
C=Ceq(1-e-t/tau), where C is the concentration of the dye in the dispersing medium, Ceq 
that at equilibrium state, t the elution time and tau is a time constant. tau increased linearly 
against weight at high contentration, suggesting controllability of the release rate of 
microcapsules by varying tri-isocyanate/di-isocyanate ratio  
4. Polyurethane microparticle as carrier of antituberculosis drug   
New polyurethane microcapsules incorporated with antituberculosis drug Is have been 
synthesized by interfacial polyaddition between toluene-2,4-diisocyanate (TDI) and various 
poly(ethylene glycol)s (PEG). Drug Is is hydrophilic water-soluble compound, and it is 
insoluble in toluene. Thus Is could be capsulated by interfacial polycondensation technique 
using water-in-toluene emulsion, which prevents transferring of Is to the external phase. 
And drug encapsulation is possible during the process of the polymer wall formation 
(Batyrbekov et al., 2009; Iskakov et al., 2004).  
Isocyanate groups react with hydroxyl groups of PEG to form polyurethane chains 
according to the Scheme (Fig.1 a). TDI can also reacts with molecules of water at the border 
of reaction to form unstable NH-COOH group, which dissociates into amine and carbon 
dioxide (Fig.1 b). Chains with amine end-group reacts with the isocyanate groups of 
growing polymer with urea segments formation. 
Polycondensation was carried out in a 1 L double-neck flask fitted with a stirrer. 
Polyethylene glycol with 4 various molecular weights 400, 600, 1000 and 1450 (Sigma, USA) 
- PEG 400, PEG 600, PEG 1000 and PEG 1450 respectively were used as diol monomers. TDI  
(Sigma, USA) was applied as a bifunctional monomer for the polycondensation. Three 
solutions were prepared separately. Solution A: 10 mg surfactant Tween 40 was dissolved in 
100 ml of toluene; solution B: x mmol diol and Is were added in y ml of water; amount of Is 
was 10, 20, and 30 mol % from PEG; solution C: 2.5 x mmol TDI was dissolved in 10 ml of 
solution A. Water/oil ratio was 1:10 vol.%. Solution B was poured into the reaction flask, 
contaning 90 ml of solution A under the stirring at 1000 rpm during 15 minutes. After the 
formation of microemulsion, solution C was added dropwise. After 180 min the 
polymerization was stopped. Microparticles were filtered, carefully washed with distillated 
water and dried at ambient conditions. Yield of polymers was estimated from the total 
amount of introduced monomers compared to the weight of polycondensation products. 
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Figure 1. Scheme of reaction between PEG and TDI with polyurethane formation. 
The completion of polycondensation process was estimated by IR-spectra from decreasing 
of the absorption band at 2270-2320 cm-1, which correspond to -N=C=O isocyanate group. IR 
spectra were obtained by a Nicolet 5700 FT-IR (USA) infrared spectrophotometer in KBr.  
In the IR-spectra of microparticles the N-H stretching vibration were observed at 3450–3300 
cm-1, absorption bands at 1740–1700 cm-1 for the C=O stretching of urethane and at 1690–
1650 cm-1 for urethane-urea formation were also present (Fig.2). Absorption bands are 
present at 1100 cm-1 for C-O-C ether group and at 2850 -2950 cm-1 for C-H. In FT-IR spectra 
of microparticles containing Is, the new stretching vibrations band appeared at 1350 cm-1, 
1000 cm-1 and 690 cm-1, which were also present in FT-IR spectra of pure Is that indicates the 
physical mechanism of Is capsulation.  
In the process of interfacial polycondensation, two PU products of reaction were detected: 
the main product - microparticles, and the secondary product - linear precipitated 
polyurethane. The increase of PEG content in water phase resulted in increased amount of 
the secondary product, and as the PEG content in water phase reached 60 vol.%, maximum 
of the secondary product was observed (about 40%).  
Decreasing PEG concentration in water phase leads to increased yield of polyurethane 
microparticles. Maximum of yield was reached at PEG concentration 22 - 27 vol.% and in 
that condition whole olygomer reacted at surface of emulsion drops with microparticles 
formation. Reduction of microparticle yield after the maximum is due mainly to increasing 
contribution of the hydrolysis process of isocyanate groups.  
Appearance of the secondary product and increase of its yield, probably, can be attributed 
to the increase of PEG concentration and results in PEG partially transfer from the water 
phase to the internal phase of toluene and the process of polycondensation between PEG 
and TDI takes place with linear polyurethane formation. At the end of reaction rate of PEG 
diffusion to surface, namely at the reaction region, seems to be a limit stage of the process. 
Reducing of PEG concentration causes to decrease of system viscosity. Effectiveness of Is 
capsulation in PU microparticles ranged from 3.4 to 41.7 % and significantly depended on 
water/PEG ratio in the water phase of emulsion.  
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Figure 2. FT-IR-spectra of polyurethane microparticles containing isoniazid (a), polyurethane 
microparticles (b) and isoniazid (c). 
Fig. 3 shows that composition of the water phase influences upon effectiveness of capsulation. 
Increase of PEG concentration results in decreasing effectiveness of capsulation and decrease 
of Is loading correspondingly. The high PEG concentration promotes miscibility of Is in the 
internal oil phase - toluene. Morphology of the surface of microparticles is very important 
factor, which affects release behavior of active agent. The wall structure depends on the 
conditions of interfacial polycondensation process, such as Mw and chemical structure of diol, 
the concentration of the monomers and other. The effect of water/PEG ratio in aqueous phase 
on morphology of microparticle was investigated. Microparticles prepared from PEG solutions 
of higher concentration have dense surface so that Is diffused much slower. At the high 
concentration of PEG reaction between PEG and TDI is significantly limited on the interface of 
the drops. Furthermore excessive PEG transfers to the external surface of   microparticles and 
reacts with TDI and less penetrable wall was formed. 
Fig.4 shows SEM photos of interfacial polycondensation products prepared by reaction 
between TDI and PEG 400 at water/PEG ratio  11,8 : 88,2 vol.% in water phase. According to 
Figs. 4a and 4b two products of polycondensation with different structure were formed. PU 
microparticles have spherical shape and size about 5 - 10 μm (Fig. 4a). The secondary 
product has fibril structure with diameter less then 500 nm (Fig 4b). The effect of water/PEG 
ratio on morphology of microparticle walls is shown in Figs. 4c and 4d. PU microparticles 
prepared at water/PEG ratio 82,4 :17,6 (Fig. 4c) have rough surface. On the contrary the 
surface of PU microparticles prepared at water/PEG ratio 11,8 : 88,2 (Fig 4d) were dense and 
smooth. 
c 
  a 
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Figure 3. The effect of PEG content in water phase on  effectiveness of encapsulation () and Is loading 
in PU microparticles (). 
 
Figure 4. SEM photographs of products of interfacial polycondensation . between TDI and PEG 400 at 
60oC. PU microparticles (a) and PU secondary product (b)synthesized at water/PEG ratio 11.8 : 88.2 in 
water phase. Surface of PU microparticles prepared at water/PEG ratio  82.4 :17.6 (c) and 11.8 : 88.2 (d) 
in water phase. 
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The release behavior of Is from PU microparticles was carried out and different conditions 
of synthesis such as water/PEG ratio, molecular weight of PEG and isoniazid concentration 
was investigated. The release behavior of microparticles loaded with isoniazid  was studied 
with ultraviolet (UV) spectroscopy. For calibration, physiological solutions of isoniazid with 
concentration ranging from 0.004 to 0.05 mg/ml were prepared and their absorption was 
measured at 263.5 nm with Jasco UV/VIS 7850 spectrophotometer (Japan). 10 mg of 
isoniazid-loaded microparticles were dispersed in 10 ml of physiological solution under 
light stirring at constant temperature 37oC. After fixed time interval 2 ml of solution was 
taken out by the squirt equipped with the special filter. The efficiency of capsulation was 
calculated as ratio of introduced isoniazid to solution B compared with amount of delivered 
isoniazid into water during 3 weeks. Isoniazid loading was weight of isoniazid (mg) 
contained in 1 g of microparticles. 
Fig. 5 shows the release behavior of Is from PU microparticles, synthesized at different 
water/PEG ratio. The most part of the drug delivered during the first three hours, then slow 
release of the residual Is was observed during the next two weeks. Microparticles prepared 
with less concentration of PEG in the water phase demonstrated faster diffusion of Is 
through walls of microparticles. The increased PEG content in water phase of reaction, 
results in decreasing Is diffusion, due to formation of PU microparticles with denser 
polymer wall. Microparticles prepared with PEG concentration 17.6, 29.4 and 41.2 vol.% 
showed the release 58 - 66 % of Is during 3 h. However, due to denser wall of microparticles 
prepared with PEG 64.7 и 88.2 vol. % demonstrated the release no more 35% of the drug 
within the same time. 
 
Figure 5. Release of Is from PU microparticles synthesized at various water/PEG ratio: ● - 82.4:17.6, o - 
70.6:29,  - 58.8:41.2,  - 35.3:64.7 and  - 11.8:88.2. 
The effect of molecular weight of PEG on release of Is from PU microparticles was 
investigated (Fig 6). Microparticles were prepared by using PEG with Mw 400, 600, 1000 and 
1450. Increasing molecular weight of soft segments (PEG) results in the increase of diffusion 
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rate of Is into solution. This phenomenon can be attributed to increasing Mw of PEG which 
leads to accelerating diffusion of water-soluble Is through hydrophilic PEG chains.  
 
Figure 6. Release of Is from PU microparticles synthesized at various Mw of PEG. MW = 400 (o), 600 (●), 
1000 () and 1450 ().  
Microparticles with different Is loading, namely 18.4, 35.3 and 65.6 mg/g were produced. In 
Fig 7 release behavior of Is is shown.  
 
Figure 7. Release of Is from PU microparticles with different Is loading:  18.4 (), 35.3 () and 65.6 
mg/g (●). 
Microparticles with higher Is loading demonstrate faster release rate of the drug due to 
increased gradient of concentrations between the external solution and core of 
microparticles. 
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PU microparticles were administrated subcutaneously to mice BL/6. Histologic analyses of 
the underskin tissue was carried out at a different period of microparticles administration in 
the mice by using electron microscope LEO F360, equipped with X-ray analyzer EDS Oxford 
ISI 300.  
Fig 8 shows histologic analyses of tissue under skin. Within 5 days of the microparticles 
deposition, the thickening of the surrounding tissue due to primary macrophage reaction 
and fibrillar tissue formation were detected as shown in Fig. 8b. On day 21, some enzymatic 
lysis of polyurethane – С(О)–NH – group probably took place (Fig. 8c) and partial 
biodegradation of PU microparticles was observed. For all experimental animals no casting-
off or necrosis of tissue were observed. 
 
Figure 8. Histological slices of tissue under mice skin 1 (а), 5 (b), and 21 (c) days after deposition of is-
containing PU microparticles to BL/6 mice provided by transparent electron microscope with 400x 
magnification. 
Thus, the data obtained in the present work have demonstrated the possibility of using PU 
microparticles as a carrier for the controlled delivery of antituberculosis drug Is. PU 
microparticles were prepared by interfacial reaction between PEG and TDI in water in 
toluene emulsion. The effect of water/PEG ratio on the morphology of microparticles and 
release behavior was shown. The low PEG content in aqueous phase results in the formation 
of microparticles with rough surface, which demonstrate faster diffusion of Is in comparison 
to PU microparticles produced from more concentrated PEG solutions, they have smooth 
surface and less penetrable walls for Is. Increased Mw of PEG and Is loading leads to 
increased diffusion rate of isoniazid from polyurethane microparticles. For PU 
microparticles administered in mice BL/6 subcutaneously, biodegradation was observed due 
to enzymatic lysis of polyurethane group. Preliminary data indicate that PU microparticles 
could be perspective carriers for controlled delivery and respirable administration of 
antituberculosis drug Is. 
5. Polyurethane foams as carriers of antituberculosis drugs 
The use of soft PU foams as carriers of antituberculosis drugs is of considerable  interest. In 
such systems pharmaceutical agents are dispersed or dissolved in the PU carrier and the 
a b c
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kinetics of drug release are generally controlled by diffusion phenomena through the 
polymer. Such systems are being used for treatment of tuberculosis-infected cavities 
(wounds, pleural empyema, bronchial fistula). It is the purpose of this chapter to show the 
possibility of using polyurethane foams as carriers of some antituberculosis agents for tuber-
culosis treatment. 
PU foams were synthesized by reaction of pre-polymer with isocyanate terminal groups 
with a small amount of branching agent and water. Other ingredients, such as catalyst and 
chain extenders, were not used in order to preserve medical purity. The scheme of synthesis 
is presented below in Fig.9.  
 
Figure 9. Scheme of PU foams synthesis. 
Antituberculosis drugs Is, ethionamide (Eth), florimicin  (Fl) and rifampicin (Rfp) were 
incorporated as fine crystals in the polymeric matrix at the stage of PU synthesis. The PU 
contained 100-300 mg of heterogeneously dispersed antituberculosis drugs.  
The release of drugs from PU was examined by immersing polymeric samples in a model 
biological medium (physiological solution, phosphate buffer pH 7.4 and Ringer-Locke 
solution) at 37°C. The amount of drug released was determined UV-spectrophotometrically 
by measuring the absorbance maximum characteristic for each drug.  
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Figure 10. Release of Eth from polyurethane foam into Ringer-Locke solution at 37oC. Drug loadings 
(mg/g PU): 100(), 200(), 300(฀). 
- 2 O=C=N-R-N=C=O + HO-R’-OH   OCN-R-NH-COO-R’-OCO-NH-R-NCO 
          diisocyanate   macrodiol                  prepolymer (R*) 
- ~ R*-NCO  +  H2O      ~  R*-NH2  +  CO2 
- ~ R*-NH2 + OCN-R*~     ~R*- NH-CO-NH- R*~ 
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All the release data show the typical pattern for a matrix-controlled mechanism. The 
cumulative amount of drugs released from the PU was linearly related to the square root of 
time and the release rate decreased with time. The process is controlled by the dissolution of 
the drug and by its diffusion through the polymer. The release is described by Fick's law 
and proceeds by first-order kinetics (Philip & Peppas, 1987). The structure of the drugs and 
their solubility influences the rate of release: the total amount of Is is released in 3-4 days, 
Eth in 5-6 days (Fig.10), Fl and Rfp in 14-16 days (Fig.11). The release time for 50% of Is is 22-
26 h, for Eth 28-30 h, for Fl and Rfp 72-76 h, respectively. The rapid release of Is and Eth in 
comparison with Fl and Rfp is due to the higher solubility of these drugs in the dissolution 
medium. Increasing the drug loading from 100 to 300 mg/g resulted in an increase in the 
release rate.  
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Figure 11. Release of Fl from PU foam into Ringer-Locke solution at 37oC. Drug loadings (mg/g PU): 
100(), 200(), 300(฀). 
Table 1 presents the values of the diffusion coefficients for drug release into different media, 
calculated for the initial release stage by a modified Higuchi equation (Higuchi, 1963). With 
increase of drug loading, the diffusion coefficient is not significantly decreased. This is 
connected with the plasticizing action of the drug, resulting in the deterioration of the 
mechanical properties of the polymeric matrix. The medium into which the drugs are 
released has no significant effect upon the diffusion coefficient. 
The release results show that the use of PU as a carrier of antituberculosis drugs provides a 
controlled release of drugs suitable for use in practical medicine, i.e. it allows prolonged 
action of drugs over some days. 
The tuberculostatic activity of drugs released from the PU was determined by diffusion into 
dense Levenshtein-Iensen nutrient medium compared with a museum strain of M. 
tuberculosis. 
It has been shown that drugs introduced into a polymeric matrix have tuberculostatic 
activity on the level of free drugs. Is formed a microorganism growth delay zone of 41 mm, 
Eth 35 mm and Fl 29 mm. 
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Drug 
Loading 
(mg/g PU) 
107 x D (cm2 s-1 ) 
Physiological 
solution 
Ringer-Locke 
solution 
Phosphate 
Buffer 
Is 
100 7,482 7,926 7,346 
200 7,026 7,150 7,158 
300 6,845 6,890 6,804 
Eth 
100 6,433 6,228 6,248 
200 6,237 5,928 6,142 
300 5,972 5,768 5,636 
Fl 
100 2,124 2,430 2,315 
200 1,980 2,068 2,112 
300 1,642 1,786 1,720 
Rfp 
100 1,116 1,224 1,226 
200 0,984 1,082 1,068 
300 0,922 0,944 0,896 
Table 1. Diffusion coefficient (D) values for drug release from polyurethane foams into different media 
at 37oC for initial stage of release. 
The efficiency of tuberculosis treatment by PU containing drugs was studied in experiments 
on guinea pigs (Batyrbekov et al., 1998). Several groups of animals, consisting of 20-25 
guinea pigs, were infected with a 6-week culture of a laboratory strain of M. tuberculosis. 
Treatment was started 2 weeks after infection. Animals were treated by weekly 
administration of PU containing 5-day doses of the drugs (PU-Is, PU-Eth or PU-Fl), or by 
daily administration of a day's dose of Is, Eth or Fl. Animals of the control group were not 
treated (C). The weights of the guinea pigs and the dimensions of ulcers at the site of 
infection were periodically determined during the experiment. All untreated animals died 
1.5-2 months after infection. The animals of the other groups were killed with  2.5 months 
after the beginning of the treatment. Guinea pigs were dissected and damage to lungs, 
livers, spleens and lymphatic ganglions was determined. The efficiency of the applied 
therapy is presented in Table 2. 
 
Group 
Index of damage, % 
Lung Liver Spleen 
Lymphatic 
ganglion 
Summary 
С 36.6 25,8 22,0 6,0 90,4 
Is 5,0 12,2 12,2 2,5 31,9 
PU-Is 4,0 11,4 12,0 2,5 29,9 
Eth 8,0 13,6 14,6 3,5 39,7 
PU-Eth 7,2 13,0 14,2 3,5 37,9 
Fl 20,2 14,4 16,8 4,8 56,2 
PU-Fl 18,8 13,0 16,6 4,4 52,0 
Table 2. Macroscopic evaluation of damage to inner organs of guinea pigs. 
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The experimental observations show that the treatment of tuberculosis in the animals by the 
polymeric systems gave the same therapeutic effect as daily treatment with single doses of 
the drugs. The most effective action was displayed by PU containing Is. This is related to its 
greater tuberculostatic activity in comparison with Eth and Fl. The animals of the PU-Is and 
Is groups had the dissemination nidi in their inner organs practically cured: guinea pigs lost 
weight slightly (4.6% and 1.2%, cf. untreated 30.6%) and had small ulcers in the place of 
infection (3.0 mm and 3.2 mm in diameter, cf. untreated 11.2 mm) (Batyrbekov et al., 1997) 
The values of weight loss and ulcer dimensions in the place of infection in animals of the 
another groups are following: 8.6% and 4.4 mm (PU-Eth); 9.0% and 4.8 mm (Eth); 11.4% and 
5.2 mm (PU-F1); 11.0% and 5.0 mm (Fl). The treatment of experimental tuberculosis by the 
polymeric systems was analogous to daily treatment with free drugs. The use of a PU carrier 
provides a stable bacteriostatic concentration of chemotherapeutic agents for 5-7 days. 
Clinical observations have shown the efficiency of PU drug delivery systems for treatment 
of tuberculosis-infected cavities (wounds,pleural empyema, bronchial fistula). 
The results obtained in the present work have shown the possibility of using PU foams as a 
matrix for drug delivery systems for prolonging the action of chemotherapeutic agents in 
tuberculosis treatment. 
6. Conclusion  
PU microparticles containing antituberculosis drugs were prepared by interfacial reaction 
between PEG and TDI in water in toluene emulsion. Two products of polycondensation 
were detected: the main product is spherical microparticles with size about 5-10 μm and the 
second product is fibrils of linear PU, which precipitate in toluene. The increase of PEG 
content in water phase results in increased amount of the secondary product, and as the 
PEG content in water phase reaches 60 vol.%, maximum of the secondary product was 
observed (about 40%). Decreasing PEG concentration in water phase leads to increased yield 
of PU microparticles. Maximum of yield was reached at PEG concentration 22 - 27 vol.% and 
in that conditions whole oligomer reacted at surface of emulsion drops with microparticles 
formation.  
The release behavior of drugs from microparticles was carried out and different conditions 
of synthesis such as water/PEG ratio, molecular weight of PEG and drug concentration was 
investigated. The increase PEG content in water phase of reaction, results in decreasing drug 
diffusion, due to formation of PU microparticles with densere polymer wall. Increasing 
molecular weight of soft segments (PEG) results in the increase of diffusion rate of drug into 
solution. This phenomenon can be attributed to increasing molecular weight of PEG which 
leads to accelerating diffusion of water-soluble drug through hydrophilic PEG chains. It was 
shown that microparticles with higher drug loading demonstrate faster release rate of the 
drug due to increased gradient of concentrations between the external solution and core of 
microparticles. 
The tuberculostatic activity of drugs released from the PU show that  drugs introduced into 
PU have antimicrobial activity identical of low molecular drugs. The efficiency of the 
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tuberculosis treatment by polyurethane drug delivery systems was shown in experiments 
on animals. The use of PU carrier provides a stable bacteriostatic concentration of the 
chemotherapeutical agents for 5-7 days. The treatment of animals infected with tuberculosis 
by PU systems was more effective than the treatment by free drugs. It was shown that is 
released from PU systems was 1.5-2 times less toxic in comparison with the low molecular 
drug. Minimal toxic action of PU on the native organism tissue was established 
hystologically. Medical-biological tests show that PU ensures sustained release of 
antituberculosis drugs and maintains effective drug concentration for long time. 
The results obtained in the present chapter have shown the possibility and outlook of PU as 
carriers of antituberculosis drugs for the delivery systems for prolonging the action of 
chemotherapeutical agents in tuberculosis treatment. 
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